9
Views
3
CrossRef citations to date
0
Altmetric
Original Article

The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management

, , &
Pages 321-324 | Accepted 23 Nov 1993, Published online: 06 Jul 2009
 

Summary

An increase in recovery of Xanthomonas maltophilia from clinical specimens at our institutions prompted, amongst other measures, an investigation of the antibiotic susceptibility patterns of the organism. Fifty-five consecutive first isolates of Xanthomonas maltophilia were obtained and antimicrobial susceptibility tests were carried out by the agar dilution method. Trimethyoprim/sulfamethoxazole was the most active antimicrobial agent (94% susceptible), with 71% susceptible to ticarcillin/clavulanic acid, 56% susceptible to ciprofloxacin and 49% susceptible to ceftazidime. Amoxycillin/clavulanic acid and imipenem were inactive (0% susceptible), while aminoglycosides were effective against only 7% of isolates. Potentiation was observed with both the combination of trimethoprim and sulfamethoxazole and the combination of ticarcillin and clavulanic acid. Familiarity with the antibiotic susceptibility pattern of Xanthomohas maltophilia as well as the potential shortcomings of the in vitro susceptibility data are important in the effective clinical management of Xanthomonas maltophilia infections.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.